141 related articles for article (PubMed ID: 33966663)
1. INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development - Historical Scope, Opportunities, and Challenges.
Sarpatwari A; Kesselheim AS
J Law Med Ethics; 2021; 49(1):6-9. PubMed ID: 33966663
[No Abstract] [Full Text] [Related]
2. The Government and Pharmaceutical Innovation: Looking Back and Looking Ahead.
Sampat BN
J Law Med Ethics; 2021; 49(1):10-18. PubMed ID: 33966646
[TBL] [Abstract][Full Text] [Related]
3. Not-for-profit drugs--no longer an oxymoron?
Sharp D
Lancet; 2004 Oct 23-29; 364(9444):1472-4. PubMed ID: 15500876
[No Abstract] [Full Text] [Related]
4. Public investments in the clinical development of bedaquiline.
Gotham D; McKenna L; Frick M; Lessem E
PLoS One; 2020; 15(9):e0239118. PubMed ID: 32946474
[TBL] [Abstract][Full Text] [Related]
5. The role of the private sector in biotechnology: research and development.
Feisee L
Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359
[No Abstract] [Full Text] [Related]
6. Capitalizing on commercialization: should congress revisit the Bayh-Dole Act?
Bruckbauer S
J Natl Cancer Inst; 2003 Oct; 95(19):1429-31. PubMed ID: 14519745
[No Abstract] [Full Text] [Related]
7. Regulating Drug Prices while Increasing Innovation.
Conti RM; Frank RG; Gruber J
N Engl J Med; 2021 Nov; 385(21):1921-1923. PubMed ID: 34767322
[No Abstract] [Full Text] [Related]
8. Non-profit Drug Research and Development at a Crossroads.
Jarosławski S; Toumi M; Auquier P; Dussart C
Pharm Res; 2018 Feb; 35(3):52. PubMed ID: 29417233
[TBL] [Abstract][Full Text] [Related]
9. The non-profit sector and the market: opportunities & challenges.
Fund Raising Manage; 2001 Nov; 32(9):42, 46-8. PubMed ID: 11881451
[TBL] [Abstract][Full Text] [Related]
10. Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?
Neumann PJ; Cohen JT; Ollendorf DA
N Engl J Med; 2021 Nov; 385(21):1923-1924. PubMed ID: 34767318
[No Abstract] [Full Text] [Related]
11. Using patent data to assess the value of pharmaceutical innovation.
Kesselheim AS; Avorn J
J Law Med Ethics; 2009; 37(2):176-83. PubMed ID: 19493065
[TBL] [Abstract][Full Text] [Related]
12. Public-private partnerships boost research on neglected diseases.
Louët S
Nat Biotechnol; 2003 Nov; 21(11):1254-5. PubMed ID: 14595339
[No Abstract] [Full Text] [Related]
13. Pricing of pharmaceuticals is becoming a major challenge for health systems.
Morgan SG; Bathula HS; Moon S
BMJ; 2020 Jan; 368():l4627. PubMed ID: 31932289
[No Abstract] [Full Text] [Related]
14. Public- and private-sector partnerships in contraceptive research and development: guiding principles.
Brooke S; Vail JG
Int J Gynaecol Obstet; 1999 Dec; 67 Suppl 2():S125-39. PubMed ID: 10661750
[TBL] [Abstract][Full Text] [Related]
15. [Commercialization of results of intellectual activities in pharmaceutical industry].
Posylkina OV; Timaniuk VN; Gladukh EV
Lik Sprava; 2002; (8):16-9. PubMed ID: 12669531
[TBL] [Abstract][Full Text] [Related]
16. Public biotech 2018-the numbers.
Morrison C; Lähteenmäki R
Nat Biotechnol; 2019 Jul; 37(7):714-721. PubMed ID: 31227821
[No Abstract] [Full Text] [Related]
17. Is there transparency in the pricing of medicines in the South African private sector?
Bangalee V; Suleman F
S Afr Med J; 2018 Feb; 108(2):82-83. PubMed ID: 29429435
[TBL] [Abstract][Full Text] [Related]
18. [Does the public sector have an independent research role in the development of drugs?].
Poulsen HE; Grønlykke TB
Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
[TBL] [Abstract][Full Text] [Related]
19. Can public financing of the private sector defeat antimicrobial resistance?
James JE
J Public Health (Oxf); 2019 Jun; 41(2):422-426. PubMed ID: 29982521
[TBL] [Abstract][Full Text] [Related]
20. Industry perspectives: ensuring vaccination of children and adolescents without financial barriers.
Feinberg MB; Gordon L
Pediatrics; 2009 Dec; 124 Suppl 5():S563-4. PubMed ID: 19948589
[No Abstract] [Full Text] [Related]
[Next] [New Search]
